HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages, has approved iQ-Check™ Enterobacteriaceae Kit for the real-time PCR detection of Enterobacteriaceae (EB) in infant formula, infant cereal with and without probiotics, and related ingredients.

Enterobacteriaceae, often used as indicators for hygiene process criteria, is a large family of gram-negative bacteria that encompasses well-known food pathogens including Salmonella, Cronobacter, or pathogenic E. coli. Presence of the pathogens provides an indicator of process effectiveness to eliminate or neutralize biological contaminants and supports prevention of recontamination. The iQ-Check Enterobacteriaceae Kit is a complete, flexible, and open solution for EB detection, enabling industrial microbiology laboratories to control and effectively adjust quality assurance procedures.

MicroVal is an independent international certification organization that provides a standardized method validation system for the microbiological analysis of food and beverages. By certifying that proprietary testing methods perform as well as internationally recognized reference methods, MicroVal certification ensures acceptance of new testing methods by regulatory and governing bodies in the food trade. Validation of the iQ-Check Enterobacteriaceae method was carried out according to the ISO-16140-2:2016 and MicroVal technical guidance, confirming its capabilities to accurately detect common pathogens in infant formula and cereals.

The latest study for the iQ-Check Enterobacteriaceae method demonstrated excellent concordance to the reference method, ISO 21528-1, validating the kits for use in infant formula and cereal testing up to 375 g. The kit was evaluated on parameters including sensitivity, relative level of detection, inclusivity and exclusivity. In addition, Bio-Rad’s iQ-Check Free DNA Removal Solution was validated as part of the workflow to remove free/dead cell DNA from the samples before PCR testing.

“Infant formula and their related ingredients must be very carefully managed, requiring strict testing and analyses prior to commercial launch, with a strong focus on Enterobacteriaceae,” said Franck Edouard, Senior Marketing Director, Food Science Division, Bio-Rad Laboratories. “Receiving MicroVal validation for our iQ-Check Enterobacteriaceae Kit for infant formula and cereal demonstrates the wide applicability of our iQ-Check kits, further cementing our position as leaders in food science”.

The method is complementary to Bio-Rad’s iQ-Check Salmonella spp. and iQ-Check Cronobacter Solution. The certificate (2018LR80) is available on the MicroVal website. The iQ-Check Enterobacteriaceae Kit is also AOAC PTM validated for powdered infant formula and environmental samples (certificate 082003).

For more information on Bio-Rad’s complete range of iQ-Check Real-Time PCR Kits, please visit https://www.bio-rad.com/iqcheck

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking StatementsThis release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.